
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Food allergy : Challenges in diagnosis, new hope for management Glue adhesives for minor skin laceration repair Pediatrics v2.0 : The role of automated vision screening technology in children






